Brca1 is expressed in human microglia and is dysregulated in human and animal model of ALS

Harun Najib Noristani1, Jean Charles Sabourin2, Yannick Nicolas Gerber3,4

  • 1Institute for Neurosciences of Montpellier (INM), INSERM U1051, 80, rue Augustin Fliche, 34091, Montpellier, Cedex 5, France. harun.noristani@ibn-lab.com.

Abstract

Insights

Microglia play a dual role in amyotrophic lateral sclerosis (ALS) pathogenesis. This study identifies Breast Cancer Susceptibility Gene 1 (Brca1) as a novel microglial marker and potential therapeutic target in ALS models and patients.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Microglia are implicated in amyotrophic lateral sclerosis (ALS) pathology.
  • Microglia may exert both neuroprotective and neurotoxic effects in motoneuron degeneration.

Purpose of the Study:

  • To identify genes involved in ALS pathology by analyzing the molecular signature of microglia in a mouse model.
  • To investigate the role of the tumor suppressor gene Brca1 in ALS.

Main Methods:

  • Transcriptomic analysis of microglia from hSOD1(G93A) mice at early symptomatic stage (P90).
  • Comparison of microglial gene profiles with motoneuron gene profiles.
  • Validation of Brca1 protein expression in human spinal microglia and ALS patients.

Main Results:

  • A unique microglial transcriptomic profile in hSOD1(G93A) mice was identified, highlighting Brca1 involvement.
  • Brca1 expression was substantiated in ALS based on comparative gene profiling.
  • Brca1 protein is specifically expressed in human spinal microglia and upregulated in ALS patients.

Conclusions:

  • Brca1 is a novel microglial marker and a potential contributor to ALS in both animal models and human patients.
  • Brca1 represents a potential therapeutic target for ALS.
  • Findings suggest investigating oncogenic proteins in neurodegenerative diseases.